drugset
drugset / Trial / NCT04566666

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

NCT04566666 ↗

Phase 2 Completed 263 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Timeline

Start
2021-03-25
Primary completion
2024-11-20
Completion
2025-08-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator SCD-044 Unknown — —

Indications

psoriasis